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February 2016 Abstracts S43immunotherapy in this preclinical GEMM model. We ul-
timately plan to test direct MYXV intralesional injection by
navigational bronchoscopy combined with immuno-
therapy to enhance immune mediated targeting of SCLC.
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Wepreviously demonstrated that proximity ligation assays
(PLA) can be utilized to detect EGFR in complex with its
major signaling adaptor GRB2, which couples the receptor
to the MAP kinase pathway to drive oncogenic prolifera-
tion. These “signaling-associated complexes” correlatewith
EGFR activity, reveal erlotinib pharmacodynamics and are
predictive of improved outcomes to EGFR-directed thera-
pies (Smith et al Science Signaling 2015). Here, we use PLA
to assess cMET signaling, which is being actively investi-
gated in late stage clinical trials in lung cancer and other
solid tumors. We found that the presence of cMET:GRB2
complexes correlates with sensitivity to cMET tyrosine ki-
nase inhibitors (TKI) and the interaction is speciﬁcally
abrogated by MET TKI as measured by biochemical ap-
proaches, cellular viability and PLA. In MET-ampliﬁed
patient-derived xenograft models of lung cancer (N¼6) we
observe MET:GRB2 complexes in regions that also stain
strongly using pMET(Y1234/5) immunohistochemistry
(IHC). Treatment of these models with single agent crizo-
tinib led to variable responses as measured by RECIST
criteria. Ongoing experiments are correlating patterns of
PLA positivity with magnitude of response to MET inhibi-
tion. In clinical cohorts of unselected non-small cell lung
cancer patients (N¼409), MET:GRB2 signaling complexes
are rare (observed in <1%), even among patients whose
tumors are highly positive for cMET protein expression as
detected by IHC. In patients with MET gene ampliﬁcation
veriﬁed by FISH, presence of MET:GRB2 complexes were
observed in 6 of 8 patients with variable intensity and
signiﬁcant spatial heterogeneity. The low rates of
MET:GRB2 signaling complexes observed in patient tissues
may potentially explain the poor response rates observed
in clinical trials targeting cMET in lung cancer. Assays that
candetect therapeutically-relevant protein complexeshave
the potential to improve patient stratiﬁcation strategies
and enable precision medicine in oncology.Natural antisense transcript
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Background: Lung cancer represents an enormous health
burden, representing the most common cause of cancer
death worldwide. The poor therapeutic outcome is largely
due to a complex molecular background as well as late
stage diagnosis, with most patients presenting unresect-
able local tumors, ormetastatic disease.Whilemutations of
driver genes is a well-known mechanism, approximately
half of all non-small cell lung cancer (NSCLC) tumorsharbor
no known clinically relevant oncogenic drivers, empha-
sizing the need to explore alternative mechanisms such as
non-coding RNAs (ncRNAs).
ncRNAs are RNA molecules that do not encode for pro-
tein, but have the ability to regulate DNA, proteins, as well
as other RNA species. These genes exhibit tissue speciﬁc
regulation and have emerged as important players in
several tumor types including lung cancer. Natural anti-
sense transcripts (NATS) are ncRNAs that are transcribed
from the opposite strand of protein coding genes. These
NATs overlapwith, and are often involved in the regulation
of, their sense counterparts. NATs can recruit regulatory
complexes to their transcriptional locus, leading to
silencing of overlapping sense partner gene transcription,
andhave recentlybeendescribed in cancer to silence tumor
suppressor genes such as CDKN2A/B. NATs are quite
prevalent as it is estimated that 25-40% of genes display
overlapping transcriptional partners, emphasizing their
potential in gene regulation. However, only a few NATs
have been characterized in cancer. Here we take an unbi-
ased approach to study NAT deregulation as a mechanism
for altered sense partner expression in NSCLC.
Methods: We performed RNA-sequencing on a set of 65
NSCLC tumors including 36 adenocarcinomas and 29
squamous cell carcinomas as well as
matched nonmalignant lung tissues. A sign-rank test was
used to identify NATs and partner genes with signiﬁ-
cantly altered expression between tumor and matched
normal tissues. These ﬁndings were validated in an
external dataset of lung tumors from TCGA. Survival
analysis was performed using a Cox Proportional hazard
model, as well as the log-rank method.
Results:We have identiﬁed a NAT of OIP5, a lung cancer
oncogene required for chromatin segregation, to be
signiﬁcantly underexpressed in NSCLC. In the same tu-
mors we ﬁnd the overlapping partner gene, OIP5 mRNA,
